Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Neutrophil-to-lymphocyte ratio and short-term mortality in patients having anti-MDA5-positive dermatomyositis with interstitial lung disease: a retrospective study.
BMC Pulm Med
January 2025
Department of Key Laboratory of Ningxia Stem Cell and Regenerative Medicine, Institute of Medical Sciences, Department of Pulmonary and Critical Care Medicine, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, 750004, China.
Background: In this study, we aimed to explore the association between baseline and early changes in the neutrophil-to-lymphocyte ratio (NLR) and the 30-day mortality rate in patients having anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis with interstitial lung disease (DM-ILD).
Methods: Overall, 263 patients with anti-MDA5 DM-ILD from four centers in China were analyzed. Multivariate logistic regression analysis was used to evaluate the impact of baseline NLR on the 30-day mortality rate in patients with anti-MDA5-positive DM-ILD.
Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.
Int J Mol Sci
January 2025
Department of Dermatology, Faculty of Medicine, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Psoriasis is a chronic inflammatory condition that is polygenic and multisystemic, impacting approximately 2-3% of the global population. The onset of this disease is influenced by an intricate interplay of genetic and environmental factors, predisposing individuals to the psoriasis phenotype. The complex pathogenesis of psoriasis contains certain key aspects found in other autoinflammatory and autoimmune dermatological diseases.
View Article and Find Full Text PDFInfections in Idiopathic Inflammatory Myopathies: Do Asians Need a Different Dose of Immunosuppression?
Int J Rheum Dis
January 2025
Department of Rheumatology, Royal Wolverhampton Hospitals NHS Trust, Wolverhampton, UK.
Recalcitrant Dermatomyositis Treated With Anifrolumab.
ACR Open Rheumatol
January 2025
Saint Louis University School of Medicine, St. Louis, Missouri.
Dermatomyositis is an idiopathic inflammatory myopathy which can present with distinctive skin features. Despite the many treatment modalities for the treatment of dermatomyositis some patients remain refractory to treatment. We present a case of a 38-year-old man with recalcitrant dermatomyositis who was successfully treated with the interferon α receptor 1-inhibiting monoclonal antibody anifrolumab.
View Article and Find Full Text PDFCase Series: The Challenge of Using Immune Checkpoint Inhibitors in Anti-Transcriptional Intermediary Factor 1 Antibody-Positive Dermatomyositis.
Int J Rheum Dis
January 2025
Department of Medicine, McGill University, Montreal, Canada.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!